There is evidence that treatment of breast and colorectal cancers exhibiting ERBB2 amplification with ERBB2 targeted drugs such as trastuzumab and pertuzumab when used in combination with EGFR inhibitors may improve outcomes (60). The gene discussed is ERBB2; the disease is colorectal cancer.